Events

EU TalentOn
SEP
Wed
14
SEP
Thu
15
SEP
Fri
16
SEP
Sat
17
SEP
Sun
18

This was 3 years ago

Location

Leiden

Programmes
Health Climate, Energy, Mobility Agro-Food, Environment Widening/Spreading Enhancing EU R&I Missions

The European Commission in collaboration with Leiden (Netherlands) as European City of Science in 2022 launched a new event “EU TalentOn”. During EU TalentOn a group of selected applicants will work in a team to come up with the best scientific solutions for challenges linked to one of the five EU missions

A call for applications for EU TalentOn is currently open for applicants between the ages of 21 and 35 years old, which are in a way connected to research and academia in a European University. The call for applications closes by July 1st

All information and the application form can be found on the EU TalentOn website

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.